Original ArticleRetro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptide
Graphical Abstract
Retro-inverso peptides attached to the surface of nanoliposomes prevent the aggregation of β-amyloid monomers into oligomers and fibrils. The ‘ffvlk’ sequence of the inhibitory peptide is designed to interact with the ‘KLVFF’ sequence on the Aβ molecule. However, Aβ could also interact with the positive charge of the ‘TAT’ sequence and Aβ oligomers, once captured, could insert themselves into the lipid bilayer of the liposomes.
Section snippets
Materials
Chemical reagents and Sepharose 4B-CL were from Sigma-Aldrich. Bovine brain sphingomyelin (Sm), cholesterol (Chol) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (mal-PEG-PE) were from Avanti Polar Lipids Inc., USA. [3H]-Sm, [3H]-propranolol, [14C]-sucrose, Ultima Gold scintillation cocktail and solvable tissue solubilizer were from PerkinElmer (Waltham, MA, USA). [14C]-Chol was provided by Quotient Bioresearch Ltd. Polycarbonate filters for liposome
Preparation and characterization of peptide inhibitor nanoparticles (PINPs)
To attach RI-OR2-TAT (Figure 1, A) covalently to the NL surface, we exploited a thiol-maleimide reaction employing an additional cysteine residue to provide the necessary thiol group.23 This thiol function at the C-terminus of RI-OR2-TAT reacted with a maleimide-functionalized phospholipid present in the NL formulation (mal-PEG-PE) (Figure 1, B). The yield of coupling was 80%-90% and, consequently, PINPs contained 2%-2.5 mol% of peptide. The total lipid recovery of NL, after the reaction with
Discussion
Here, we linked RI-OR2-TAT covalently to the surface of NL composed of sphingomyelin and cholesterol. This lipid formulation has been widely utilized in vivo for therapeutic purposes and displays good blood circulation times, good biocompatibility, and high resistance to hydrolysis.26 In addition, the 130-140 nm diameter is optimal for moving at an appreciable rate through the brain extracellular space.27 We found that the presence of the carrier appears to increase the potency of RI-OR2-TAT as
References (41)
- et al.
Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus
Brain Res
(2002) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
Anal Biochem
(1976)Colorimetric determination of phospholipids with ammonium ferrothiocyanate
Anal Biochem
(1980)- et al.
In vitro model for evaluating drug transport across the blood–brain barrier
Adv Drug Deliv Rev
(1999) - et al.
Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood–brain barrier model
Nanomedicine
(2011) - et al.
Current methods for attaching targeting ligands to liposomes and nanoparticles
J Pharm Sci
(2004) - et al.
Effect of curcumin-associated and lipid ligand functionalised nanoliposomes on aggregation of the Alzheimer's Aβ peptide
Nanomedicine
(2011) - et al.
Ionic effects of the Alzheimer's disease β amyloid precursor protein and its metabolic fragments
Trends Neurosci
(1997) - et al.
Lipid-based nanoparticles with high binding affinity for amyloid-β 1-42 peptide
Biomaterials
(2010) - et al.
Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood–brain-barrier: implications for therapy of Alzheimer disease
Nanomedicine
(2014)
The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1 42 peptides in vitro and to amyloid deposits in post-mortem tissue
Biomaterials
Therapeutics of Alzheimer's disease: past, present and future
Neuropharmacology
Alzheimer's Disease International World Alzheimer Report 2010 The Global Economic Impact of Dementia
Diffusible, nonfibrillar ligands derived from Aβ 1 42 are potent central nervous system neurotoxins
Proc Natl Acad Sci U S A
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
Nature
Selective neuronal degeneration induced by soluble oligomeric amyloid β protein
FASEB J
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Nat Neurosci
Aβ oligomers – a decade of discovery
J Neurochem
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Nat Rev Mol Cell Biol
β-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin
J Neurosci
Cited by (0)
The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 212043, and from The Alzheimer's Society UK (grant number 210 (AS-PG-2013-032)). There were also contributions from Lancaster University's Defying Dementia campaign.
Competing interests: The University of Lancaster has filed a patent (WO2013054110) on intellectual property related to this work, based on inventions of DA and MT. The patent has been licensed to MAC Clinical Research, UK.
The authors thank Pierre-Olivier Couraud from Institut National de la Santé et de la Recherche Médicale (INSERM, Paris, France) for providing the hCMEC/D3 cells.
- 1
Maria Gregori and Mark Taylor contributed equally to this paper.